Table 1 Characteristics of the patients with HF.

From: Differential protein profiling as a potential multi-marker approach for obese patients with heart failure: A retrospective study

 

All HF

non-obese (NOB) HF

obese (OB) HF

p

(N = 16)

(N = 8)

(N = 8)

Age, y

63 ± 9

61 ± 8

65 ± 11

0.38

BMI, kg/m²

29.5 ± 6.3

24.2 ± 1.9

34.8 ± 4.1

 < 0.01

Cardiovascular risk factors

Hypertensive, % (n)

31 (5)

12 (1)

50 (4)

0.28

T2-Diabetes, % (n)

37 (6)

0 (0)

75 (6)

0.01

Dyslipedemia, % (n)

56 (9)

37 (3)

75 (6)

0.31

Smoking, % (n)

12 (2)

12 (1)

12 (1)

1.00

Alcool, % (n)

12 (2)

0 (0)

25 (2)

0.47

Heart failure etiology

Ischemic CM, % (n)

62 (10)

75 (6)

50 (4)

0.61

Dilated CM, % (n)

37 (6)

25 (2)

50 (4)

0.61

Medication

ACEIs, % (n)

94 (15)

100 (8)

87 (7)

1.00

Beta-blockers, % (n)

94 (15)

100 (8)

87 (7)

1.00

Diuretics, % (n)

94 (15)

75 (8)

87 (7)

1.00

Vitamin K antagonists, % (n)

44 (7)

50 (4)

37 (3)

1.00

Antiplatelet agents, % (n)

56 (9)

62 (5)

50 (4)

1.00

Statines, % (n)

62 (10)

75 (6)

50 (4)

0.61

Insulin, % (n)

19 (3)

0 (0)

37 (3)

0.20

Admission labs

BNP, pmol/ml

237 [116–1054]

976 [141–7284]

160 [26–600]

0.05

Creatinin, μmol/L

124 ± 10.74

122 ± 37

125 ± 48

0.89

C reactive protein, mg/L

6.5 [3.8–12.0]

10.2 [3.5–27.9]

6.2 [2.6–10.9]

0.35

Na+, mmol/L

137.9 ± 3.9

136.3 ± 3.9

139.5 ± 3.4

0.10

K+, mmol/L

4.1 ± 0.3

4.1 ± 0.3

4.2 ± 0.3

0.73

Total Proteins, g/L

73 ± 11

68 ± 8

79 ± 11

0.04

Hemoglobin, g/dl

14.3 ± 1.9

13.8 ± 2.3

14.7 ± 1.6

0.39

Hematocrit, %

42 ± 5

40 ± 6

44 ± 4

0.21

Leucocytes,x 109/L

7.9 ± 2.2

6.8 ± 1.5

8.9 ± 2.5

0.06

Bilirubin, mg/L

6.0 [4.2–6.0]

6.0 [4.5–6.5]

5.0 [4.0–6.0]

0.51

TGO (ASAT), UI

28.0 ± 9.5

23.1 ± 3.9

34.8 ± 11.3

0.02

TGP (ALAT), UI

32.9 ± 20.3

24.7 ± 6.2

44.4 ± 28.2

0.04

Triglyceride, g/L (0,6–1,7)

1.0 [0.7–1.5]

1.0 [0.7–7.4]

1.5 [0.7–3.6]

0.52

LDL, g/L

0.80 [0.65–0.99]

0.85 [0.52–1.14]

0.80 [0.65–1.35]

0.77

HDL, g/L

0.40 [0.40–0.50]

0.40 [0.25–0.55]

0.50 [0.40–0.55]

0.23

Cholesterol total, g/L (1,5–2,2)

1.5 [1.4–2.0]

1.5[1.0–2.3]

1.7 [1.4–2.1]

0.56

Admission vitals

MAP, mmHg

91 ± 10

87 ± 7

94 ± 10

0.45

HR, Bpm

70 ± 5.38

74 ± 21

67 ± 21

0.54

Echocardiography

    

LVEF, %

33 ± 15

25 ± 7

42 ± 17

0.02

LVEF < 30%, % (n)

50 (8)

75 (6)

25 (2)

0.13

NYHA class

    

I,% (n)

6 (1)

0

12 (1)

1.00

II,% (n)

68 (11)

75 (6)

62 (5)

1.00

III,% (n)

25 (4)

25 (2)

25 (2)

1.00

Outcomes

All cases mortality

25 (5)

50 (5)

0

0.02

  1. HF, heart failure; BMI, body mass index; CM, cardiomyopathy; ACEIs, angiotensin-converting enzyme inhibitors; BNP, B-type natriuretic peptide concentration; TGP (ALT), alanine aminotransferase; TGO (AST), aspartate aminotransferase; MAP, Mean Arterial Pressure; HR, Heart rate; LDL, low density lipoprotein; HDL, high density protein; LVEF, left ventricular ejection fraction; NYHA class, New York Heart Association functional classification. Results are presented as mean ± SEM or ± confidence intervals. Bold values are significant vs NOB group.
Back to article page